SANUWAVE Health (SNWV) sells UltraMIST, the only FDA-cleared non-contact ultrasound wound therapy in the U.S. Revenue grew 35% to $44.1M in FY2025 with 77% gross margins. The stock is down 50% in the past year, tracking the CMS-driven destruction of skin substitute companies — a category SANUWAVE does not belong to.

What the filing says

The 10-K filed March 26, 2026 tells two stories.

The business is strong. Revenue $44.1M (+35%), gross margin 77% (+200bps), operating income $4.9M. Consumable volume grew 24%, system volume grew 67%. The installed base hit 1,292 active systems. A new reseller channel launched in 2025 and represents 34% of system sales in year one. Q4 implied revenue of $13.4M shows acceleration from Q3's $11.3M.

UltraMIST runs a razor/blade model — sell the system, sell recurring single-use applicators at high margin. Consumables are 58% of revenue with 3% annual pricing power. The business has a Category 1 CMS reimbursement code (CPT 97610) and over 60 patents.

The governance is broken. A material restatement covers seven periods: FY2024 and all quarterly filings for 2024 and 2025. Two issues — a sales tax nexus compliance failure spanning 2022-2025 ($4.9M accrued liability), and an ASC 606 revenue overstatement of $300K on extended warranty discounts. CEO and CFO certified controls were not effective. Material weaknesses are not remediated. The filing is unusually frank about the root cause: "insufficient accounting resources and technical expertise to appropriately analyze and apply US GAAP."

Going concern doubt was real as recently as Q2 2025, resolved by a JPMorgan Chase refinancing in September — a $23M term loan at SOFR+350bps replacing a distressed specialty lender. The company is in covenant compliance at year-end, but true levered free cash flow is approximately $0.6M. The $11.8M in GAAP net income is noise: $8.1M from a non-cash warrant liability collapse and $5M from a one-time patent sale, both gone in FY2026. Stock-based compensation tripled to $4.9M (11% of revenue), with $10.3M still unrecognized.

What the market thinks

SNWV trades at $18.85 — $162M market cap, $172M enterprise value, 3.9x trailing revenue.

Comparable small-cap medical device companies growing 25-35% with 70%+ gross margins trade at 8-15x revenue. Sanara MedTech, growing at a similar rate with 93% gross margins in wound care, trades at 15.7x. At 3.9x, the market prices SNWV as a 5-10% grower or assigns material probability of value destruction.

The stock's 1-year performance tracks almost exactly with MiMedx (MDXG, -48%) and Organogenesis (ORGO, -48%). All three are classified as "wound care." RSI is 16.8. Two analysts cover the stock, both at Buy with $53-55 targets. Short interest is 11%, 10.6 days to cover.

Why the gap exists

CMS enacted the most significant wound care reimbursement change in decades via the CY2026 Medicare Physician Fee Schedule Final Rule. Skin substitutes were reclassified from ASP+6% reimbursement to a flat $127.14 per square centimeter. Medicare skin substitute spending had ballooned from $256M in 2019 to over $10B in 2024. CMS projects $19.6B in savings over ten years.

This is devastating for skin substitute companies. Organogenesis disclosed "a significant year-over-year decline in revenue in the first quarter of fiscal year 2026." MiMedx acknowledged a "headwind to both Advanced Wound Management sales and profitability in 2026."

SANUWAVE's CPT 97610 is not a skin substitute code. It covers non-contact low-frequency ultrasound therapy — a completely different pathway. The company confirmed this in a November 3, 2025 press release: "Reimbursement for the 97610 code for UltraMIST products remains materially unchanged for 2026 with payment for treatment provided in the physician office, home visit, long-term care, and hospital settings remaining within $2-4 of 2025 rates."

A factor regression over the trailing 8 months quantifies the damage. SNWV's returns load onto a wound care peer factor (equal-weighted MDXG/ORGO) with a beta of 0.46 (p<0.001), explaining 12.4% of total variance. In plain terms: roughly 20 percentage points of SNWV's 48% decline came from trading in lockstep with skin substitute companies whose economics are being destroyed. The remaining 83% of variance is idiosyncratic — the governance overhang.

Why hasn't this corrected? Three reasons. Two analysts at sub-$250M market cap — the inference chain requires domain knowledge nobody is applying. The restatement landed at the same time as the CMS selloff, so the market conflated governance problems with regulatory destruction. And the auditor change looked like a red flag until you check the PCAOB records: the prior auditor was Marcum LLP, fined $13M by the SEC for systemic quality control failures across 600+ SPAC clients. Marcum lost 36 net audit clients in Q1 2025. The new auditor, Baker Tilly, is a Top 10 firm. The departure was part of an industry-wide exodus, and Baker Tilly discovering the sales tax issue is the system working as intended.

Risks

Governance spiral. Material weaknesses are not remediated. The sales tax liability of $4.9M uses minimum-of-range accounting — the filing states "actual liabilities may differ materially." No voluntary disclosure agreements with states are mentioned. Another restatement or a Nasdaq deficiency notice would confirm governance problems are systemic rather than fixable.

Thin free cash flow. At $0.6M levered FCF on $44M revenue, the company cannot self-fund its debt service ($5.75M principal in 2026). Growth must translate to operating leverage, or the revolver gets drawn.

Reseller pull-forward. The new channel drove 34% of system sales in its first year. If resellers built inventory rather than reflecting end-user demand, 2026 system sales decelerate. Q1 2026 guidance of $9.6-10.3M — roughly flat year-over-year — may already signal this.

Single product, no pipeline. R&D is $1.35M (3% of revenue). If CMS changes CPT 97610 billing guidelines, or if Vaporox (co-marketing with MiMedx) scales faster than expected, there is no fallback.

Insider selling. Manchester Management, an affiliated fund, sold $5.1M at ≈$30.70 in December 2025 — the largest insider transaction in the stock's recent history. Not management, but informed.

Catalysts

Earnings call, March 27, 2026. FY2026 guidance and whether skin substitute reps are converting to sell UltraMIST.

Q1 2026 10-Q, due ~May 15. First post-restatement filing. Revenue versus $9.6-10.3M guide, material weakness progress, sales tax updates. This is the decision point.

Proxy DEF 14A, due by April 30. CEO comp, insider ownership, clawback outcome. Governance quality depends on this.

Peer divergence, H1-H2 2026. As MDXG and ORGO report CMS-hit revenue, SNWV's continued growth should force the market to recognize the differentiation. The wound care peer correlation should decay toward zero.

What would change our mind

A second restatement or Nasdaq deficiency notice — governance problems are systemic, not fixable.

CMS modifications to CPT 97610 — any tightening of coverage criteria, prior authorization, or rate reductions. The thesis depends on this pathway being stable.

Management insider selling at current levels. No CEO or COO selling has occurred. If it starts, the information asymmetry flips.

Q1 2026 revenue below $9.6M guidance floor — the CMS disruption is affecting even non-skin-substitute wound care, or the reseller channel was pure pull-forward.

Evidence